MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

被引:85
作者
Bai, Xue [1 ]
Kong, Yan [1 ]
Chi, Zhihong [1 ]
Sheng, Xinan [1 ]
Cui, Chuanliang [1 ]
Wang, Xuan [1 ]
Mao, Lili [1 ]
Tang, Bixia [1 ]
Li, Siming [1 ]
Lian, Bin [1 ]
Yan, Xieqiao [1 ]
Zhou, Li [1 ]
Dai, Jie [1 ]
Guo, Jun [1 ]
Si, Lu [1 ]
机构
[1] Peking Univ, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst, Dept Renal Canc & Melanoma,Minist Educ Beijing, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
LARGE-SCALE ANALYSIS; BRAF V600E MUTATION; CLINICOPATHOLOGICAL FEATURES; CANCER; NRAS; NF1; PROGRESSION; TUMORS;
D O I
10.1158/1078-0432.CCR-17-0980
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Ethnic differences are conspicuous in melanoma. This study is to obtain a comprehensive view of a genomic landscape and a better understanding of the correlations of gene mutation status with clinicopathologic characteristics and disease prognosis in the Asian population. Experimental Design: A total of 2,793 melanoma patient samples were retrospectively collected and analyzed for mutations in C-KIT, BRAF, NRAS, and PDGFRA coding regions and telomerase reverse transcriptase (TERT) promoter region by Sanger sequencing. Mutations were correlated to clinicopathologic features and overall survival. Results: The incidences of somatic mutations within the BRAF, NRAS, C-KIT, TERT-228, TERT-250, and PDGFRA genes were 23.7%, 10.4%, 8.0%, 5.9%, 5.5%, and 1.4%, respectively. Hotspot mutations accounted for 95.8% and 87.2% of BRAF and NRAS mutations, respectively; meanwhile, C-KIT and PDGFRA mutations showed more heterogeneity. BRAF, C-KIT, and NRAS mutations were mutually exclusive. BRAF, C-KIT, NRAS, and numbers of gene mutations of the MAPK pathway were all independent negative prognostic factors (P = 0.007, other P < 0.001, respectively). In acral melanoma, BRAF, C-KIT, and NRAS mutations were all independent prognostic factors of worse overall survival (all P < 0.001), whereas in mucosal melanoma, only C-KIT was (P = 0.006). Although correlated with BRAF mutations (P = 0.001 and P < 0.001 for C228T and C250T, respectively), TERT promoter gene mutations were not correlated with overall survival (P = 0.406 and 0.256, respectively). Conclusions: The MAPK pathway and TERT promoter gene mutations are differentially represented in the Asian population. Mutations in BRAF, C-KIT, and NRAS have prognostic values that vary by melanoma subtypes. Clinical treatment targeting these critical pathways should be aimed directly at these poor-prognosis subpopulations for maximum potential impact. (C) 2017 AACR.
引用
收藏
页码:6120 / 6127
页数:8
相关论文
共 43 条
[1]   Genomic Classification of Cutaneous Melanoma [J].
Akbani, Rehan ;
Akdemir, Kadir C. ;
Aksoy, B. Arman ;
Albert, Monique ;
Ally, Adrian ;
Amin, Samirkumar B. ;
Arachchi, Harindra ;
Arora, Arshi ;
Auman, J. Todd ;
Ayala, Brenda ;
Baboud, Julien ;
Balasundaram, Miruna ;
Balu, Saianand ;
Barnabas, Nandita ;
Bartlett, John ;
Bartlett, Pam ;
Bastian, Boris C. ;
Baylin, Stephen B. ;
Behera, Madhusmita ;
Belyaev, Dmitry ;
Benz, Christopher ;
Bernard, Brady ;
Beroukhim, Rameen ;
Bir, Natalie ;
Black, Aaron D. ;
Bodenheimer, Tom ;
Boice, Lori ;
Boland, Genevieve M. ;
Bono, Riccardo ;
Bootwalla, Moiz S. ;
Bosenberg, Marcus ;
Bowen, Jay ;
Bowlby, Reanne ;
Bristow, Christopher A. ;
Brockway-Lunardi, Laura ;
Brooks, Denise ;
Brzezinski, Jakub ;
Bshara, Wiam ;
Buda, Elizabeth ;
Burns, William R. ;
Butterfield, Yaron S. N. ;
Button, Michael ;
Calderone, Tiffany ;
Cappellini, Giancarlo Antonini ;
Carter, Candace ;
Carter, Scott L. ;
Cherney, Lynn ;
Cherniack, Andrew D. ;
Chevalier, Aaron ;
Chin, Lynda .
CELL, 2015, 161 (07) :1681-1696
[2]   Genetics of melanoma progression: the rise and fall of cell senescence [J].
Bennett, Dorothy C. .
PIGMENT CELL & MELANOMA RESEARCH, 2016, 29 (02) :122-140
[3]  
Bradford PT, 2009, ARCH DERMATOL, V145, P427, DOI 10.1001/archdermatol.2008.609
[4]   Clinical significance of BRAF mutations in metastatic melanoma [J].
Chang D.Z. ;
Panageas K.S. ;
Osman I. ;
Polsky D. ;
Busam K. ;
Chapman P.B. .
Journal of Translational Medicine, 2 (1)
[5]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[6]   Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases [J].
Chi, Zhihong ;
Li, Siming ;
Sheng, Xinan ;
Si, Lu ;
Cui, Chuanliang ;
Han, Mei ;
Guo, Jun .
BMC CANCER, 2011, 11
[7]   NF1 tumor suppressor gene function: Narrowing the GAP [J].
Cichowski, K ;
Jacks, T .
CELL, 2001, 104 (04) :593-604
[8]   NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics [J].
Cirenajwis, Helena ;
Lauss, Martin ;
Ekedahl, Henrik ;
Torngren, Therese ;
Kvist, Anders ;
Saal, Lao H. ;
Olsson, Hakan ;
Staaf, Johan ;
Carneiro, Ana ;
Ingvar, Christian ;
Harbst, Katja ;
Hayward, Nicholas K. ;
Jonsson, Goran .
MOLECULAR ONCOLOGY, 2017, 11 (04) :438-451
[9]   Distinct sets of genetic alterations in melanoma [J].
Curtin, JA ;
Fridlyand, J ;
Kageshita, T ;
Patel, HN ;
Busam, KJ ;
Kutzner, H ;
Cho, KH ;
Aiba, S ;
Bröcker, EB ;
LeBoit, PE ;
Pinkel, D ;
Bastian, BC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147
[10]   Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib [J].
Dai, Jie ;
Kong, Yan ;
Si, Lu ;
Chi, Zhihong ;
Cui, Chuanliang ;
Sheng, Xinan ;
Mao, Lili ;
Li, Siming ;
Lian, Bin ;
Yang, Ruifeng ;
Liu, Shujing ;
Xu, Xiaowei ;
Guo, Jun .
CLINICAL CANCER RESEARCH, 2013, 19 (24) :6935-6942